期刊文献+

1例急性心梗PCI术后出现左心室附壁血栓的抗凝药学监护

Personalized Pharmaceutical Monitoring of Left Ventricular Mural Thrombus after PCI in A Case of Acute Myocardial Infarction
下载PDF
导出
摘要 目的 探讨1例急性心梗经皮冠状动脉介入术(PCI)后出现左心室附壁血栓(Left ventricular wall thrombus,LVT)的个性化药学监护。方法 1例急性心梗PCI术后出现LVT初始给予华法林抗凝治疗后患者手臂及大腿出现大块瘀斑,临床药师协助分析出血原因并制定个性化的治疗建议。结果 医师采纳临床药师建议,患者抗凝治疗3个月后LVT消失。结论 临床药师通过协助临床医师处理分析药物不良反应,开展抗凝药学监护可明显提高急性心梗PCI术后出现LVT患者用药的安全性和有效性。 OBJECTIVE Exploring personalized pharmaceutical monitoring for a case of left ventricular wall thrombus(LVT) after PCI for acute myocardial infarction.METHODS One case of acute myocardial infarction after PCI showed LVT.After initial anticoagulation treatment with warfarin,the patient developed large bruises on the arms and thighs.Clinical pharmacists assisted in analyzing the cause of bleeding and developing personalized treatment recommendations.RESULTS The physician followed the advice of a clinical pharmacist and the patient′s left ventricular thrombus disappeared after 3 months of anticoagulation treatment.CONCLUSION Clinical pharmacists assist clinical physicians in handling and analyzing adverse drug reactions,Conducting anticoagulant pharmaceutical monitoring can significantly improve the safety and effectiveness of medication for patients with LVT after PCI for acute myocardial infarction.
作者 吕盼 金玉婷 尹丽珍 LV Pan;JIN Yu-ting;YIN Li-zhen(Department of Pharmacy,Tonglu Hospital of Traditional Chinese Medicine,Tonglu 311500,China)
出处 《海峡药学》 2024年第11期92-95,共4页 Strait Pharmaceutical Journal
关键词 急性心梗 左心室附壁血栓 抗凝 药学监护 Acute myocardial infarction Left ventricular mural thrombus Anticoagulation Pharmaceutical monitoring
  • 相关文献

参考文献10

二级参考文献96

  • 1许俊堂.口服抗凝药的作用机制与临床应用(上)[J].中国医刊,2006,41(1):51-52. 被引量:22
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3肖铁卉,王士雯,陈艳明,陈琪,张新勇,徐斌.心肌梗死后室壁瘤合并附壁血栓形成的相关因素分析[J].临床荟萃,2007,22(7):464-466. 被引量:7
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652. 被引量:1
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867. 被引量:1
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868. 被引量:1
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293. 被引量:1
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719. 被引量:1
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S. 被引量:1
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S. 被引量:1

共引文献675

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部